At a glance
ClinicalIndex Comparison RecordPhase 2Active· 195 enrolled
Drug / intervention
Letrozole +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS): A Randomized Phase II Study of Palbociclib With Letrozole Versus Letrozole Alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma
In Brief
A Phase 2 clinical trial evaluating Letrozole, Tamoxifen, and 2 other interventions for Breast Cancer. Active but no longer recruiting, targeting 195 participants across 11 sites.
Detailed Summary
This research study is evaluating how well Breast Cancer responds to preoperative treatment with Endocrine treatment in combination with a drug called Palbociclib or Endocrine treatment alone as possible treatments for Hormone Receptor Positive Breast Cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2Active
2016201720182019202020212022202320242025202620272028202920302031
First PostedMay 2016
Enrollment StartMay 2016
Primary CompletionFeb 2022
TodayJul 2026
Study CompletionApr 2031
First PostedMay 6, 2016
Enrollment StartMay 24, 2016
Primary CompletionFeb 1, 2022
Study CompletionApr 1, 2031
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 10.2 years ago
Interventions
Letrozoledrug
Tamoxifendrug
Palbociclibdrug
Endocrine Therapydrug